Research
Hormonal
Several emerging oral agents have demonstrated promising efficacy, achieving weight loss of ≥10% in clinical trials.
Practitioners may consider these oral agents as effective options for weight management.
StrongSupportsmedium confidence
Several agents have demonstrated promising efficacy, achieving weight loss of ≥10% in clinical trials while also exhibiting favourable safety profiles.
Why this rating
Based on the mention of clinical trials.
Source
Novel oral agents in anti‐obesity pharmacotherapy: A narrative review
Assaf Buch et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16618
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →